Approval · Notice of Compliance 11102 · 2010
ILARIS: Notice of Compliance 11102
Issued February 26, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11102
- Date
- February 26, 2010
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Immunomodulatory agent - a selective interleukin-1 beta (IL-1beta) inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ILARIS | 02344939 | Cancelled Post Market |
Medicinal ingredients
- CANAKINUMAB 150 MG per VIAL